Multivalent Vaccines Industry Research Report 2025

Summary

According to APO Research, the global Multivalent Vaccines market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Multivalent Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Multivalent Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Multivalent Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Multivalent Vaccines include Bavarian Nordic (Denmark), CSL Limited (Australia), Daiichi Sankyo (Japan), Emergent BioSolutions, Inc(US), GlaxoSmithKline, plc (U.K.), MedImmune, LLC (US), Mitsubishi Tanabe Pharma Corporation (Japan), Panacea Biotec (India) and Protein Sciences Corporation (US), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Multivalent Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multivalent Vaccines.

The report will help the Multivalent Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Multivalent Vaccines market size, estimations, and forecasts are provided in terms of sales volume (W Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Multivalent Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Multivalent Vaccines Segment by Company

Bavarian Nordic (Denmark)
CSL Limited (Australia)
Daiichi Sankyo (Japan)
Emergent BioSolutions, Inc(US)
GlaxoSmithKline, plc (U.K.)
MedImmune, LLC (US)
Mitsubishi Tanabe Pharma Corporation (Japan)
Panacea Biotec (India)
Protein Sciences Corporation (US)
Serum Institute of India Pvt. Ltd. (India)
Astellas Pharma Inc. (Japan)
Pfizer, Inc(US)
Merck & Co., Inc(US)
Johnson & Johnson (US)
Sanofi Pasteur SA (France)
Multivalent Vaccines Segment by Type

Toxoid Vaccines
Live Attenuated Vaccines
Conjugate Vaccines
Inactivated and Subunit Vaccines
Recombinant Vaccines
Multivalent Vaccines Segment by Application

Pediatrics
Adults
Multivalent Vaccines Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East Middle East & Africa
Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multivalent Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Multivalent Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multivalent Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Multivalent Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Multivalent Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Multivalent Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Multivalent Vaccines Market Size (2020-2031)
2.2.2 Global Multivalent Vaccines Sales (2020-2031)
2.2.3 Global Multivalent Vaccines Market Average Price (2020-2031)
2.3 Multivalent Vaccines by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Toxoid Vaccines
2.3.3 Live Attenuated Vaccines
2.3.4 Conjugate Vaccines
2.3.5 Inactivated and Subunit Vaccines
2.3.6 Recombinant Vaccines
2.4 Multivalent Vaccines by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Pediatrics
2.4.3 Adults
3 Market Competitive Landscape by Manufacturers
3.1 Global Multivalent Vaccines Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Multivalent Vaccines Sales (W Units) of Manufacturers (2020-2025)
3.3 Global Multivalent Vaccines Revenue of Manufacturers (2020-2025)
3.4 Global Multivalent Vaccines Average Price by Manufacturers (2020-2025)
3.5 Global Multivalent Vaccines Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Multivalent Vaccines, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Multivalent Vaccines, Product Type & Application
3.8 Global Manufacturers of Multivalent Vaccines, Established Date
3.9 Global Multivalent Vaccines Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Bavarian Nordic (Denmark)
4.1.1 Bavarian Nordic (Denmark) Company Information
4.1.2 Bavarian Nordic (Denmark) Business Overview
4.1.3 Bavarian Nordic (Denmark) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Bavarian Nordic (Denmark) Multivalent Vaccines Product Portfolio
4.1.5 Bavarian Nordic (Denmark) Recent Developments
4.2 CSL Limited (Australia)
4.2.1 CSL Limited (Australia) Company Information
4.2.2 CSL Limited (Australia) Business Overview
4.2.3 CSL Limited (Australia) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.2.4 CSL Limited (Australia) Multivalent Vaccines Product Portfolio
4.2.5 CSL Limited (Australia) Recent Developments
4.3 Daiichi Sankyo (Japan)
4.3.1 Daiichi Sankyo (Japan) Company Information
4.3.2 Daiichi Sankyo (Japan) Business Overview
4.3.3 Daiichi Sankyo (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Daiichi Sankyo (Japan) Multivalent Vaccines Product Portfolio
4.3.5 Daiichi Sankyo (Japan) Recent Developments
4.4 Emergent BioSolutions, Inc(US)
4.4.1 Emergent BioSolutions, Inc(US) Company Information
4.4.2 Emergent BioSolutions, Inc(US) Business Overview
4.4.3 Emergent BioSolutions, Inc(US) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Emergent BioSolutions, Inc(US) Multivalent Vaccines Product Portfolio
4.4.5 Emergent BioSolutions, Inc(US) Recent Developments
4.5 GlaxoSmithKline, plc (U.K.)
4.5.1 GlaxoSmithKline, plc (U.K.) Company Information
4.5.2 GlaxoSmithKline, plc (U.K.) Business Overview
4.5.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.5.4 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Portfolio
4.5.5 GlaxoSmithKline, plc (U.K.) Recent Developments
4.6 MedImmune, LLC (US)
4.6.1 MedImmune, LLC (US) Company Information
4.6.2 MedImmune, LLC (US) Business Overview
4.6.3 MedImmune, LLC (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.6.4 MedImmune, LLC (US) Multivalent Vaccines Product Portfolio
4.6.5 MedImmune, LLC (US) Recent Developments
4.7 Mitsubishi Tanabe Pharma Corporation (Japan)
4.7.1 Mitsubishi Tanabe Pharma Corporation (Japan) Company Information
4.7.2 Mitsubishi Tanabe Pharma Corporation (Japan) Business Overview
4.7.3 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Portfolio
4.7.5 Mitsubishi Tanabe Pharma Corporation (Japan) Recent Developments
4.8 Panacea Biotec (India)
4.8.1 Panacea Biotec (India) Company Information
4.8.2 Panacea Biotec (India) Business Overview
4.8.3 Panacea Biotec (India) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Panacea Biotec (India) Multivalent Vaccines Product Portfolio
4.8.5 Panacea Biotec (India) Recent Developments
4.9 Protein Sciences Corporation (US)
4.9.1 Protein Sciences Corporation (US) Company Information
4.9.2 Protein Sciences Corporation (US) Business Overview
4.9.3 Protein Sciences Corporation (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Protein Sciences Corporation (US) Multivalent Vaccines Product Portfolio
4.9.5 Protein Sciences Corporation (US) Recent Developments
4.10 Serum Institute of India Pvt. Ltd. (India)
4.10.1 Serum Institute of India Pvt. Ltd. (India) Company Information
4.10.2 Serum Institute of India Pvt. Ltd. (India) Business Overview
4.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Portfolio
4.10.5 Serum Institute of India Pvt. Ltd. (India) Recent Developments
4.11 Astellas Pharma Inc. (Japan)
4.11.1 Astellas Pharma Inc. (Japan) Company Information
4.11.2 Astellas Pharma Inc. (Japan) Business Overview
4.11.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Portfolio
4.11.5 Astellas Pharma Inc. (Japan) Recent Developments
4.12 Pfizer, Inc(US)
4.12.1 Pfizer, Inc(US) Company Information
4.12.2 Pfizer, Inc(US) Business Overview
4.12.3 Pfizer, Inc(US) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Pfizer, Inc(US) Multivalent Vaccines Product Portfolio
4.12.5 Pfizer, Inc(US) Recent Developments
4.13 Merck & Co., Inc(US)
4.13.1 Merck & Co., Inc(US) Company Information
4.13.2 Merck & Co., Inc(US) Business Overview
4.13.3 Merck & Co., Inc(US) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Merck & Co., Inc(US) Multivalent Vaccines Product Portfolio
4.13.5 Merck & Co., Inc(US) Recent Developments
4.14 Johnson & Johnson (US)
4.14.1 Johnson & Johnson (US) Company Information
4.14.2 Johnson & Johnson (US) Business Overview
4.14.3 Johnson & Johnson (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.14.4 Johnson & Johnson (US) Multivalent Vaccines Product Portfolio
4.14.5 Johnson & Johnson (US) Recent Developments
4.15 Sanofi Pasteur SA (France)
4.15.1 Sanofi Pasteur SA (France) Company Information
4.15.2 Sanofi Pasteur SA (France) Business Overview
4.15.3 Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.15.4 Sanofi Pasteur SA (France) Multivalent Vaccines Product Portfolio
4.15.5 Sanofi Pasteur SA (France) Recent Developments
5 Global Multivalent Vaccines Market Scenario by Region
5.1 Global Multivalent Vaccines Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Multivalent Vaccines Sales by Region: 2020-2031
5.2.1 Global Multivalent Vaccines Sales by Region: 2020-2025
5.2.2 Global Multivalent Vaccines Sales by Region: 2026-2031
5.3 Global Multivalent Vaccines Revenue by Region: 2020-2031
5.3.1 Global Multivalent Vaccines Revenue by Region: 2020-2025
5.3.2 Global Multivalent Vaccines Revenue by Region: 2026-2031
5.4 North America Multivalent Vaccines Market Facts & Figures by Country
5.4.1 North America Multivalent Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Multivalent Vaccines Sales by Country (2020-2031)
5.4.3 North America Multivalent Vaccines Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Multivalent Vaccines Market Facts & Figures by Country
5.5.1 Europe Multivalent Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Multivalent Vaccines Sales by Country (2020-2031)
5.5.3 Europe Multivalent Vaccines Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Multivalent Vaccines Market Facts & Figures by Country
5.6.1 Asia Pacific Multivalent Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Multivalent Vaccines Sales by Country (2020-2031)
5.6.3 Asia Pacific Multivalent Vaccines Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Multivalent Vaccines Market Facts & Figures by Country
5.7.1 South America Multivalent Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Multivalent Vaccines Sales by Country (2020-2031)
5.7.3 South America Multivalent Vaccines Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.8 Middle East and Africa Multivalent Vaccines Market Facts & Figures by Country
5.8.1 Middle East and Africa Multivalent Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Multivalent Vaccines Sales by Country (2020-2031)
5.8.3 Middle East and Africa Multivalent Vaccines Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Multivalent Vaccines Sales by Type (2020-2031)
6.1.1 Global Multivalent Vaccines Sales by Type (2020-2031) & (W Units)
6.1.2 Global Multivalent Vaccines Sales Market Share by Type (2020-2031)
6.2 Global Multivalent Vaccines Revenue by Type (2020-2031)
6.2.1 Global Multivalent Vaccines Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Multivalent Vaccines Revenue Market Share by Type (2020-2031)
6.3 Global Multivalent Vaccines Price by Type (2020-2031)
7 Segment by Application
7.1 Global Multivalent Vaccines Sales by Application (2020-2031)
7.1.1 Global Multivalent Vaccines Sales by Application (2020-2031) & (W Units)
7.1.2 Global Multivalent Vaccines Sales Market Share by Application (2020-2031)
7.2 Global Multivalent Vaccines Revenue by Application (2020-2031)
7.2.1 Global Multivalent Vaccines Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Multivalent Vaccines Revenue Market Share by Application (2020-2031)
7.3 Global Multivalent Vaccines Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Multivalent Vaccines Value Chain Analysis
8.1.1 Multivalent Vaccines Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Multivalent Vaccines Production Mode & Process
8.2 Multivalent Vaccines Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Multivalent Vaccines Distributors
8.2.3 Multivalent Vaccines Customers
9 Global Multivalent Vaccines Analyzing Market Dynamics
9.1 Multivalent Vaccines Industry Trends
9.2 Multivalent Vaccines Industry Drivers
9.3 Multivalent Vaccines Industry Opportunities and Challenges
9.4 Multivalent Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings